44 related articles for article (PubMed ID: 16507327)
1. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
[TBL] [Abstract][Full Text] [Related]
2. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
[TBL] [Abstract][Full Text] [Related]
3. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Gréen H; Hasmats J; Kupershmidt I; Edsgärd D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Brandén E; Koyi H; Peterson C; Lundeberg J
Clin Cancer Res; 2016 Jan; 22(2):366-73. PubMed ID: 26378035
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Ledermann JA; Gabra H; Jayson GC; Spanswick VJ; Rustin GJ; Jitlal M; James LE; Hartley JA
Clin Cancer Res; 2010 Oct; 16(19):4899-905. PubMed ID: 20719935
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intracavitary carboplatin chemotherapy for treatment of pleural carcinomatosis in cats: a retrospective study of eight cases.
Floch F; Boissy L; Lanore D; Sayag D; Serres F
J Feline Med Surg; 2020 Feb; 22(2):84-90. PubMed ID: 30720396
[TBL] [Abstract][Full Text] [Related]
6. A Novel Model to Prevent Venous Thromboembolism in Patients with Lung Cancer.
Wu X; Lin B; Zhu H
Altern Ther Health Med; 2024 Mar; 30(3):146-151. PubMed ID: 37883756
[TBL] [Abstract][Full Text] [Related]
7. Successful chemotherapy with Carboplatin and s-1 for thymic carcinoma: a case report.
Igawa S; Yanagisawa N; Ishihara M; Kimura M; Maki S; Otani S; Sasaki J; Masuda N
Case Rep Oncol; 2013; 6(3):526-30. PubMed ID: 24348388
[TBL] [Abstract][Full Text] [Related]
8. Small cell lung cancer.
Kalemkerian GP; Akerley W; Bogner P; Borghaei H; Chow L; Downey RJ; Gandhi L; Ganti AK; Govindan R; Grecula JC; Hayman J; Heist RS; Horn L; Jahan TM; Koczywas M; Moran CA; Niell HB; O'Malley J; Patel JD; Ready N; Rudin CM; Williams CC;
J Natl Compr Canc Netw; 2011 Oct; 9(10):1086-113. PubMed ID: 21975911
[No Abstract] [Full Text] [Related]
9. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L; Douillard JY; Koralewski P; Manegold C; Smit EF; Reyes JM; Chang GC; John WJ; Peterson PM; Obasaju CK; Lahn M; Gandara DR
J Clin Oncol; 2006 Mar; 24(9):1428-34. PubMed ID: 16549837
[TBL] [Abstract][Full Text] [Related]
10. An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S; Rubin SJS; Zerihun M; Qvit N
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139428
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions.
Man HSJ; Moosa VA; Singh A; Wu L; Granton JT; Juvet SC; Hoang CD; de Perrot M
Front Genet; 2023; 14():1281538. PubMed ID: 38075698
[TBL] [Abstract][Full Text] [Related]
12. Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials.
Kawano T; Inokuchi J; Eto M; Murata M; Kang JH
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834162
[TBL] [Abstract][Full Text] [Related]
13. Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation.
Raguraman P; Balachandran AA; Chen S; Diermeier SD; Veedu RN
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771719
[TBL] [Abstract][Full Text] [Related]
14. Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.
Sadeghi MM; Salama MF; Hannun YA
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073823
[TBL] [Abstract][Full Text] [Related]
15. The complexities of PKCα signaling in cancer.
Black AR; Black JD
Adv Biol Regul; 2021 May; 80():100769. PubMed ID: 33307285
[TBL] [Abstract][Full Text] [Related]
16. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.
Zhang LL; Cao FF; Wang Y; Meng FL; Zhang Y; Zhong DS; Zhou QH
Clin Transl Oncol; 2015 May; 17(5):371-7. PubMed ID: 25351171
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for lung neoplasms.
Vachani A; Moon E; Wakeam E; Haas AR; Sterman DH; Albelda SM
Clin Chest Med; 2011 Dec; 32(4):865-85. PubMed ID: 22054892
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C in heart failure: a therapeutic target?
Palaniyandi SS; Sun L; Ferreira JC; Mochly-Rosen D
Cardiovasc Res; 2009 May; 82(2):229-39. PubMed ID: 19168855
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
